Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kevzara

Sanofi reception

Sanofi bets on DiCE to find oral alternatives to injectable drugs

Makes the US biotech's discovery engine a core part of its R&D portfolio

- PMLiVE

First round to Amgen in PCSK9 patent battle with Sanofi

US court concludes Praluent has infringed rival cholesterol drug Repatha

Sanofi reception

Sanofi’s sarilumab beats Humira in head-to-head trial

Rheumatoid arthritis candidate was more effective than AbbVie's market-leader

- PMLiVE

Sanofi and Merck & Co dissolve longstanding vaccines alliance

Lacklustre sales at Sanofi Pasteur MSD prompts split

- PMLiVE

Lantus sales decline as competition heats up at Sanofi

Brand affected by biosimilars, growth of other new drugs and pricing pressure

dengue fever mosquito

EMA creates Zika virus task force

Will aid research and development of vaccines and medicines

National Institute for Health and Care Excellence NICE logo

NICE backs Repatha but rejects cholesterol rival Praluent

New draft guidance marks a U-turn on Amgen's drug but knocks back Sanofi treatment

dengue fever mosquito

Sanofi embarks on Zika vaccine hunt

Begins research programme as WHO declares the virus a global emergency

- PMLiVE

Tresiba safer than insulin glargine, says Novo Nordisk

Trial compares its basal insulin with Sanofi's Lantus

Sanofi reception

Sanofi and Novartis snap up immuno-oncology candidates

Separate licensing deals see the firms look to catch up with the category's leaders

- PMLiVE

Mylan buys into six biosimilars, including Orencia candidate

Deal with Momenta bolsters biosimilars pipeline for new products

- PMLiVE

Sanofi abandons inhaled insulin pact with Mannkind

Poor sales prompt return of Afrezza rights less than a year after its launch

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links